Physician profile
John Angus Dasher
NPI 1689137580
$1,397.13
in general payments reported to CMS, 2019-2025
31 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $66.99 · 2024: $253 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.18 |
| Education | $210.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $191.90 | 2025 | Erleada, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $139.82 | 2024-2025 | Opdivo |
| Incyte Corporation | $114.10 | 2024-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $105.30 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $88.79 | 2025 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $76.97 | 2025 | |
| Seagen INC. | $66.99 | 2022 | |
| Pfizer INC. | $65.45 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.57 | 2025 | |
| Beone Medicines USA, INC. | $41.64 | 2025 | Tevimbra, Brukinsa |
| Celgene Corporation | $33.75 | 2025 | Breyanzi, Reblozyl |
| Pharmaessentia USA Corporation | $32.60 | 2025 | Besremi |
| Exelixis INC. | $29.74 | 2025 | Cabometyx |
| Iovance Biotherapeutics, INC. | $26.56 | 2025 | Amtagvi |
| Emd Serono, INC. | $25.47 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $25.26 | 2025 | Lorbrena |
| Puma Biotechnology, INC. | $24.65 | 2025 | |
| Stemline Therapeutics INC. | $23.22 | 2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $22.76 | 2025 | |
| Adaptive Biotechnologies Corporation | $22.73 | 2025 | Clonoseq |
| Geron Corporation | $21.08 | 2025 | Rytelo |
| Genzyme Corporation | $20.61 | 2025 | |
| Agios Pharmaceuticals, INC. | $17.99 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $16.95 | 2025 | |
| Fennec Pharmaceuticals, INC. | $16.57 | 2025 | Fyarro |
| Abbvie INC. | $16.11 | 2025 | |
| Sumitomo Pharma America, INC. | $15.77 | 2025 | Orgovyx |
| Janssen Scientific Affairs, LLC | $15.69 | 2024 | Rybrevant |
| Recordati_rare_diseases_inc. | $14.88 | 2025 | Enjaymo |
| Pharmacosmos Therapeutics INC. | $14.19 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.